Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Ovarian Neoplasms 2Insulin-Like Growth Factor I, Resistance To 2Colorectal Neoplasms 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 8Oxaliplatin 7Leucovorin 6Irinotecan 6Gemcitabine 5fludarabine 3aldesleukin 3Pemetrexed 3Nivolumab 3Cyclophosphamide 3Cetuximab 3Capecitabine 35,10-methylenetetrahydrofolic acid 3dehydroftorafur 2cobimetinib 2Specimen Handling 2Panitumumab 2Interleukin-2 2Docetaxel 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tivozanib 1sodium propionate 1rucaparib 1rilotumumab 1repotrectinib 1regorafenib 1pralsetinib 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gastrointestinal Neoplasms × ganitumab × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡